Mansour Nourah Al, Mahmeed Ali Al, Bindayna Khalid
Microbiology, Immunology and Infectious Diseases, College of Medicine and Medical Sciences, Arabian Gulf University, Bahrain.
Biochem Biophys Rep. 2023 Jul 11;35:101511. doi: 10.1016/j.bbrep.2023.101511. eCollection 2023 Sep.
Sepsis is a life-threatening condition characterized by a dysregulated host response to infection. Early and accurate diagnosis of sepsis is crucial for timely intervention and improved patient outcomes. In recent years, there has been growing interest in identifying reliable biomarkers to aid in the diagnosis of sepsis. This study aims to evaluate the levels of two potential biomarkers, high-mobility group box 1 (HMGB1) and human β-defensin 3 (HBD-3), and compare their diagnostic efficacy in sepsis. We aimed to assess HMGB-1 and HBD-3 levels in sepsis and assess the combined diagnostic validity of HMGB-1 and HBD-3. In this case-control study, the plasma concentration of HMGB-1 and HBD-3 was measured using an enzyme-linked immunosorbent assay (ELISA). Two groups, totaling 144 people, were formed; 66 patients treated in the ICU for sepsis were included in the patient group. 78 Blood donors from the Salmaniya Medical Complex Blood Bank who had no prior infection or inflammatory disease made up the Control group. The statistical computations were performed using the STATA 8® statistical software tool (StataCorp LP, College Station, TX, USA). In patients' mean HMGB-1 levels were 2.1442 ng/ml, compared to 0.62141 ng/ml in the control group. The mean HBD-3 level was 1068.453 ng/ml in sepsis patients versus 589.935 ng/ml in controls. A significant difference between the two groups has been observed in both biomarkers (P < 0.05). The sensitivity of HMGB-1 was 75.8% and 41.3%, respectively. The sensitivity and specificity of HBD-3 were 63.6% and 93.5%, respectively. The levels of HMGB-1 and HBD-3 between healthy and septic subjects varied significantly. HMGB-1 and HBD-3 levels in the blood tested together might accurately identify sepsis. These findings contribute to the growing body of evidence supporting the utility of biomarkers in sepsis diagnosis, and may ultimately aid in the development of more effective diagnostic strategies for sepsis management.
脓毒症是一种危及生命的病症,其特征为宿主对感染的反应失调。脓毒症的早期准确诊断对于及时干预和改善患者预后至关重要。近年来,人们越来越关注识别可靠的生物标志物以辅助脓毒症的诊断。本研究旨在评估两种潜在生物标志物——高迁移率族蛋白B1(HMGB1)和人β-防御素3(HBD-3)的水平,并比较它们在脓毒症诊断中的效能。我们旨在评估脓毒症患者中HMGB-1和HBD-3的水平,并评估HMGB-1和HBD-3联合诊断的有效性。在这项病例对照研究中,采用酶联免疫吸附测定(ELISA)法测量HMGB-1和HBD-3的血浆浓度。共分为两组,总计144人;患者组包括66名在重症监护病房接受脓毒症治疗的患者。对照组由78名来自萨勒曼尼亚医疗中心血库的无既往感染或炎症性疾病的献血者组成。使用STATA 8®统计软件工具(美国德克萨斯州大学站市StataCorp LP公司)进行统计计算。患者的平均HMGB-1水平为2.1442纳克/毫升,而对照组为0.62141纳克/毫升。脓毒症患者的平均HBD-3水平为1068.453纳克/毫升,而对照组为589.935纳克/毫升。在这两种生物标志物中均观察到两组之间存在显著差异(P < 0.05)。HMGB-1的敏感性分别为75.8%和41.3%。HBD-3的敏感性和特异性分别为63.6%和93.5%。健康受试者和脓毒症患者之间的HMGB-1和HBD-3水平差异显著。同时检测血液中的HMGB-1和HBD-3水平可能准确识别脓毒症。这些发现为支持生物标志物在脓毒症诊断中的效用的越来越多的证据做出了贡献,并最终可能有助于开发更有效的脓毒症管理诊断策略。